• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Poland·Healthcare·NEU.WA
Share

NEUCA S.A. Stocks

PLN 718Last Updated 26.06.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

PLN 872.13M

PLN 718
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribution, the development and marketing of proprietary drug brands, and a comprehensive healthcare services division. This healthcare arm specifically encompasses outpatient care, clinical trials, and telemedicine. Beyond these core areas, NEUCA S.A. provides an extensive array of additional services, including marketing and advertising support, agency functions, financial solutions, logistics through road cargo transport, accounting and bookkeeping, software development, information technology support, and specialized services for hospitals. The company also offers various insurance products—covering health, property, and other personal lines—and operates its own network of medical supply stores. Established in 1990 as Torfarm SA, the company rebranded to NEUCA S.A. in April 2010.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of NEU.WA is 975 and suggests 35.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.06.2026 03:48

OpenAI restricted access to the new version of ChatGPT at the request of the Trump administration

27.06.2026 03:12

Moderna shares hit a two-year high after a 13% surge. It's all about a new treatment

27.06.2026 01:53

The U.S. launched strikes against Iran in response to an attack on a commercial vessel in the Strait of Hormuz

27.06.2026 01:07

The Nasdaq fell 4% following the worst week of the year for semiconductor stocks

27.06.2026 00:12

Bitcoin is at a two-year low. When will it be safe to start buying it again?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026